Latest On Citius Pharmaceuticals, Inc (CTXR):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-12 22:21 EST | News | Citius Pharmaceuticals GAAP EPS of -$0.07 misses by $0.02 | N/A |  |
| 2023-05-04 10:53 EST | News | Citius Pharmaceuticals slumps 16% on $15M offering | N/A | |
| 2023-04-24 17:08 EST | News | Citius Pharma down 8% despite close to end of late-stage Mino-Lok trial | N/A | |
| 2023-03-31 03:24 EST | News | Citius extends gains on advancing efforts to spin off oncology asset | N/A | |
| 2023-03-01 09:40 EST | News | Citius Pharmaceuticals: Balanced Risk-Reward Bet, Near-Term Catalysts | N/A | |
| 2023-02-26 09:00 EST | News | Citius Pharmaceuticals: Diverse Development Portfolio Backs Up A Problematic Lead Therapy | N/A | |
| 2023-02-11 14:43 EST | News | Citius Pharmaceuticals GAAP EPS of -$0.02 | N/A | |
| 2022-12-23 06:31 EST | News | Citius Pharmaceuticals GAAP EPS of -$0.23 beats by $0.01 | N/A | |
| 2022-12-02 03:43 EST | News | Citius stock rises as I/ONTAK gets FDA review for rare blood cancer | N/A | |
| 2022-11-22 00:39 EST | News | Citius Pharmaceuticals secures $3.6M through NJEDA | N/A | |
| 2022-11-08 10:30 EST | News | Citius Pharmaceuticals: Large Price Action Imminent From Catalysts Within 60 Days | N/A | |
| 2022-09-28 17:23 EST | News | Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK | N/A | |
| 2022-09-24 00:46 EST | News | Citius gains on clinical collaboration to study cancer candidate | N/A | |
| 2022-08-12 01:01 EST | News | Citius Pharmaceuticals GAAP EPS of -$0.06 | N/A | |
| 2022-07-13 00:39 EST | News | Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK | N/A | |
| 2022-07-06 04:24 EST | News | Citius Pharmaceuticals: Hoping For A Turnaround Strategy | N/A | |
| 2022-05-25 15:29 EST | News | Citius Pharma to spinoff its immunotherapy I/ONTAK into a new publicly-traded company | N/A | |
| 2022-05-13 09:56 EST | News | Citius Pharmaceuticals GAAP EPS of -$0.05 beats by $0.02 | N/A | |
| 2022-05-06 23:53 EST | News | Citius to add overseas sites to Phase 3 trial for antibiotic lock therapy | N/A | |
| 2022-04-13 16:17 EST | News | Critical Care Biopharma - Citius Pharmaceuticals | N/A | |
| 2022-04-13 16:17 EST | News | Citius Pharma realigns management to support commercialization of two late-stage products | N/A | |
| 2022-04-06 14:09 EST | News | Citius stock soars 16% as I/ONTAK seen to equal discontinued cancer drug in phase 3 trial | N/A | |
| 2022-03-28 19:19 EST | News | Citius: 2022 Is A Year Of Catalysts | N/A | |
| 2022-02-11 01:35 EST | News | Citius Pharmaceuticals GAAP EPS of -$0.06 in-line | N/A | |
| 2021-12-16 05:04 EST | News | Citius Pharmaceuticals reports FY results | N/A | |
| 2021-09-26 17:36 EST | News | Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization | N/A | |
| 2021-09-07 11:31 EST | News | Citius Pharmaceuticals acquires license for lymphoma treatment E7777 from Dr. Reddy's | N/A | |
| 2021-08-13 11:38 EST | News | Citius Pharmaceuticals reports Q3 results | N/A | |
| 2021-07-21 03:11 EST | News | Citius Pharmaceuticals set to join Russell 2000 Index | N/A | |
| 2021-07-21 03:10 EST | News | Citius Pharmaceuticals provides late-stage Mino-Lok trial timeline update | N/A | |
| 2021-07-21 03:03 EST | News | Citius Pharmaceuticals adds John Laffey to scientific advisory board | N/A | |
| 2021-07-21 03:03 EST | News | Citius: Halt For Superiority On The Horizon | N/A | |
| 2021-07-21 02:45 EST | News | Citius Pharma stock tanks 16% despite "positive" DMC recommendation to continue late-stage Mino-Lok trial | N/A | |
| 2021-07-21 02:44 EST | News | Provention Bio among healthcare gainers; Arrowhead Pharmaceuticals and Citius Pharma among losers | N/A | |
| 2021-04-26 18:45 EST | News | Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results | N/A | |
| 2021-04-17 21:55 EST | News | Checking In On Citius Pharmaceuticals | N/A | |
| 2021-02-21 23:25 EST | Analyst Rating | The Analyst Target Price has increased from $5 to $6. | Buy | |
| 2021-02-17 19:29 EST | News | Citius Pharma slips 8% on capital raise | N/A | |
| 2021-02-12 11:25 EST | Earnings Estimate | An EPS average of $0.17 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-02-12 07:29 EST | Financials | Company financials have been released. | Neutral | |
| 2021-01-28 23:35 EST | Analyst Rating | The Analyst Target Price has decreased from $5.5 to $5. | Neutral | |
| 2021-01-25 15:21 EST | News | Citius Pharma to raise $20M through share sale | N/A | |
| 2020-12-18 11:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-17 03:31 EST | Earnings Estimate | An EPS average of $2.22 is estimated for the 2022 year. | Buy | |
| 2020-12-17 03:31 EST | Earnings Estimate | An EPS average of $0.24 is estimated for the quarter ending on March 31, 2021. | Buy | |
| 2020-12-13 03:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-06 23:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-24 07:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 15:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-16 17:49 EST | News | Citius Pharmaceuticals: Phase 3 Catalyst Countdown And Ready For Take Off | N/A | |
About Citius Pharmaceuticals, Inc (CTXR):
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
General
- Name Citius Pharmaceuticals, Inc
- Symbol CTXR
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 10
- Last Split Factor1:15
- Last Split Date2017-06-09
- Fiscal Year EndSeptember
- IPO Date2017-07-06
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.citiuspharma.com
View More
Valuation
- Forward PE 1.29
- Price/Book (Most Recent Quarter) 9.93
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.34
- Next Year EPS Estimate $0.31
- Next Quarter EPS Estimate $0.16
- Return on Assets -44%
- Return on Equity -93%
- Earnings Per Share -$0.82
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 242.77 million
- EBITDA -15601637
- Analyst Target Price $6
- Book Value Per Share $0.45
View More
Share Statistics
- Shares Outstanding 125.79 million
- Shares Float 67.62 million
- % Held by Insiders 2215%
- % Held by Institutions 13.89%
- Shares Short 10.11 million
- Shares Short Prior Month 2.8 million
- Short Ratio 0.37
- Short % of Float 9%
- Short % of Shares Outstanding 8%
View More
Technicals
- Beta 1.55
- 52 Week High $2.5
- 52 Week Low $0.44
- 50 Day Moving Average 1.72
- 200 Day Moving Average 1.21
View More
Dividends
- Dividend Date 2017-06-09
- ExDividend Date N/A
- Dividend Yield 0%
View More
Citius Pharmaceuticals, Inc (CTXR) Dividend Calendar:
CTXR's last dividend payment was made to shareholders on June 9, 2017.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Citius Pharmaceuticals, Inc (CTXR) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-03 | $N/A | -$0.15 | $0.16 | -193.75% |
| 2020-09-30 | 2020-12-16 | $N/A | -$0.07 | -$0.10 | 30% |
| 2020-06-30 | 2020-08-14 | $N/A | -$0.11 | -$0.11 | 0% |
| 2020-03-31 | 2020-05-14 | $N/A | -$0.13 | -$0.11 | -18.18% |
| 2019-12-31 | 2020-02-13 | $N/A | -$0.15 | -$0.14 | -7.14% |
| 2019-09-30 | 2019-12-16 | $N/A | -$0.16 | -$0.14 | -14.29% |
| 2019-06-30 | 2019-08-14 | $N/A | -$0.20 | ||
| 2019-03-31 | 2019-05-15 | $N/A | -$0.20 | -$0.20 | 0% |
| 2018-12-31 | 2019-02-14 | $N/A | -$0.22 | -$0.21 | -4.76% |
| 2018-09-30 | 2018-12-11 | $N/A | -$0.15 | ||
| 2018-06-30 | 2018-08-14 | $N/A | -$0.19 | -$0.32 | 40.63% |
| 2018-03-31 | 2018-05-11 | $N/A | -$0.44 | ||
| 2017-12-31 | 2018-03-20 | $N/A | -$0.38 | ||
| 2017-09-30 | 2017-12-13 | $N/A | -$0.44 | ||
| 2017-06-30 | 2017-06-30 | $N/A | -$0.49 | ||
| 2017-03-31 | 2017-03-31 | $N/A | -$0.55 | ||
| 2016-12-31 | 2016-12-31 | $N/A | -$0.44 | ||
| 2016-09-30 | 2016-09-30 | $N/A | -$0.53 | ||
| 2016-06-30 | 2016-06-30 | $N/A | -$0.75 | ||
| 2016-03-31 | 2016-03-31 | $N/A | -$0.35 | ||
| 2015-12-31 | 2015-12-31 | $N/A | -$0.53 | ||
| 2015-09-30 | 2015-09-30 | $N/A | -$0.40 | ||
| 2015-06-30 | 2015-06-30 | $N/A | -$0.38 | ||
| 2015-03-31 | 2015-03-31 | $N/A | -$0.17 | ||
| 2014-12-31 | 2014-12-31 | $N/A | -$0.41 |
Citius Pharmaceuticals, Inc (CTXR) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Apr 30 2020 | Mar 31 2020 |
|---|---|---|---|---|---|
| Research Development | 6.19 million | 1.49 million | N/A | N/A | N/A |
| Income Before Tax | -8.15 million | -4.12 million | N/A | N/A | N/A |
| Selling General Administrative | 1.97 million | 2.65 million | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | -8.14 million | -4.08 million | N/A | N/A | N/A |
| Operating Income | -8.16 million | -4.14 million | N/A | N/A | N/A |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | N/A |
| Net Income From Continuing Operations | -8.15 million | -4.12 million | N/A | N/A | N/A |
| Net Income Applicable to Common Shares | -8.15 million | -4.12 million | -4.68 million | -4.68 million | -4.42 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Apr 30 2020 | Mar 31 2020 | Jan 31 2020 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | 44611 | 287264 | 287264 | N/A | -22901 |
| Total Cash Flow from Investing Activities | N/A | -1831 | -1831 | N/A | -1831 |
| Net Borrowings | N/A | 164583 | 164583 | N/A | 164583 |
| Total Cash Flow from Financial Activities | 8.7 million | N/A | N/A | 6.03 million | N/A |
| Change to Operating Activities | 330065 | 173060 | 173060 | N/A | -532047 |
| Change in Cash | 5.34 million | N/A | N/A | 1.56 million | N/A |
| Total Cash from Operating Activities | -3.36 million | -3.99 million | -3.99 million | -4.47 million | -4.47 million |
| Depreciation | 39127 | N/A | N/A | 47278 | N/A |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 349033 | 197761 | 197761 | N/A | 464853 |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Apr 30 2020 | Mar 31 2020 |
|---|---|---|---|---|---|
| Total Liabailities | 9.51 million | 10.1 million | N/A | N/A | 4.05 million |
| Total Stockholder Equity | 25.2 million | 33.67 million | N/A | N/A | 22.44 million |
| Other Current Liabilities | 163423 | N/A | N/A | 28.74 million | N/A |
| Total Assets | 35.31 million | 43.77 million | N/A | N/A | 26.49 million |
| Common Stock | 55577 | 55577 | 46316 | N/A | N/A |
| Other Current Assets | 1.28 million | N/A | N/A | 46316 | N/A |
| Retained Earnings | -81.14 million | -70.59 million | -66.47 million | -66.47 million | -64.57 million |
| Other Liabilities | N/A | 4.99 million | 4.99 million | 4.99 million | N/A |
| Other Assets | N/A | 57093 | 57093 | 57093 | N/A |
| Cash | 4.3 million | 13.86 million | N/A | 8.52 million | 4.34 million |
| Total Current Liabilities | 3.55 million | 4.1 million | N/A | 3.61 million | 3.11 million |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 1424 | 987781 | 1.03 million | 1.03 million | N/A |
| Total Current Assets | 5.58 million | 13.98 million | N/A | 8.57 million | 4.39 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 25.2 million | 4.92 million | -4734 | -4734 | N/A |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | 164583 | 164583 | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 3.21 million | 1.86 million | N/A | 1.81 million | 1.52 million |
Citius Pharmaceuticals, Inc (CTXR) Chart:
Citius Pharmaceuticals, Inc (CTXR) News:
Below you will find a list of latest news for Citius Pharmaceuticals, Inc (CTXR) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Citius Pharmaceuticals, Inc (CTXR) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0.01 | CALL | 5 | 2066 | 270.55 | FALSE | 0.01 | 0 |
| 2024-05-17 | 5 | 0.04 | CALL | 0 | 28 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0.05 | CALL | 0 | 2 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 2 | PUT | 1 | 2 | 581.12 | TRUE | 2 | 0 |
| 2024-05-17 | 5 | 4.38 | PUT | 0 | 0 | 789.04 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 6.59 | PUT | 0 | 0 | 934.57 | TRUE | 0 | 0 |
| 2024-06-21 | 2.5 | 0.04 | CALL | 0 | 62 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | PUT | 0 | 0 | 298.38 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 0 | PUT | 0 | 0 | 458.81 | TRUE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | PUT | 0 | 0 | 554.44 | TRUE | 0 | 0 |
| 2024-08-16 | 2.5 | 0.15 | CALL | 3 | 3848 | 240.79 | FALSE | 0.06 | 0.67 |
| 2024-08-16 | 5 | 0.04 | CALL | 0 | 7 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 2.5 | 1.75 | PUT | 0 | 1 | 219.58 | TRUE | 0 | 0 |
| 2024-08-16 | 5 | 0 | PUT | 0 | 0 | 220.54 | TRUE | 0 | 0 |
| 2024-08-16 | 7.5 | 6.7 | PUT | 0 | 0 | 411.52 | TRUE | 0 | 0 |
| 2024-11-15 | 2.5 | 0.15 | CALL | 1301 | 4370 | 178.32 | FALSE | -0.05 | -0.25 |
| 2024-11-15 | 5 | 0.1 | CALL | 0 | 20 | 356.1 | FALSE | 0 | 0 |
| 2024-11-15 | 7.5 | 0.05 | CALL | 0 | 49 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 2.5 | 0 | PUT | 0 | 0 | 281.98 | TRUE | 0 | 0 |
| 2024-11-15 | 5 | 0 | PUT | 0 | 0 | 314.94 | TRUE | 0 | 0 |
| 2024-11-15 | 7.5 | 0 | PUT | 0 | 0 | 377.35 | TRUE | 0 | 0 |
Latest CTXR Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 110 | $0.9501 |
| Jun 13, 2022 7:59 PM EST | 1000 | $0.9501 |
| Jun 13, 2022 7:59 PM EST | 200 | $0.95 |
| Jun 13, 2022 7:59 PM EST | 100 | $0.9501 |
| Jun 13, 2022 7:59 PM EST | 73 | $0.9501 |
Citius Pharmaceuticals, Inc (CTXR) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020015902/0001213900-20-015902-index.htm |
| 2020-04-16 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1506251/000000000020003314/0000000000-20-003314-index.htm |
| 2020-06-11 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1506251/000000000020005207/0000000000-20-005207-index.htm |
| 2020-09-18 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1506251/000000000020008820/0000000000-20-008820-index.htm |
| 2020-02-06 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1506251/000091957420000776/0000919574-20-000776-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1506251/000091957420001645/0000919574-20-001645-index.htm |
| 2019-10-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390019020117/0001213900-19-020117-index.htm |
| 2019-10-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390019020119/0001213900-19-020119-index.htm |
| 2019-10-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390019020122/0001213900-19-020122-index.htm |
| 2019-10-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390019020124/0001213900-19-020124-index.htm |
| 2019-10-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390019020126/0001213900-19-020126-index.htm |
| 2019-11-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390019021804/0001213900-19-021804-index.htm |
| 2019-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390019022028/0001213900-19-022028-index.htm |
| 2019-12-16 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1506251/000121390019026259/0001213900-19-026259-index.htm |
| 2019-12-16 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1506251/000121390019026269/0001213900-19-026269-index.htm |
| 2019-12-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390019026521/0001213900-19-026521-index.htm |
| 2019-12-20 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1506251/000121390019026699/0001213900-19-026699-index.htm |
| 2019-12-20 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1506251/000121390019026703/0001213900-19-026703-index.htm |
| 2020-01-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020001566/0001213900-20-001566-index.htm |
| 2020-02-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020002349/0001213900-20-002349-index.htm |
| 2020-02-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020002480/0001213900-20-002480-index.htm |
| 2020-02-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020003094/0001213900-20-003094-index.htm |
| 2020-02-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1506251/000121390020003577/0001213900-20-003577-index.htm |
| 2020-02-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020003992/0001213900-20-003992-index.htm |
| 2020-02-18 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1506251/000121390020004157/0001213900-20-004157-index.htm |
| 2020-02-18 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1506251/000121390020004160/0001213900-20-004160-index.htm |
| 2020-02-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020004257/0001213900-20-004257-index.htm |
| 2020-02-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020004698/0001213900-20-004698-index.htm |
| 2020-04-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020008291/0001213900-20-008291-index.htm |
| 2020-04-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020008765/0001213900-20-008765-index.htm |
| 2020-04-10 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1506251/000121390020008985/0001213900-20-008985-index.htm |
| 2020-04-17 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1506251/000121390020009473/0001213900-20-009473-index.htm |
| 2020-04-24 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1506251/000121390020010056/0001213900-20-010056-index.htm |
| 2020-04-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020010246/0001213900-20-010246-index.htm |
| 2020-04-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020010431/0001213900-20-010431-index.htm |
| 2020-05-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020011769/0001213900-20-011769-index.htm |
| 2020-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1506251/000121390020012286/0001213900-20-012286-index.htm |
| 2020-05-15 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1506251/000121390020012584/0001213900-20-012584-index.htm |
| 2020-05-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020012809/0001213900-20-012809-index.htm |
| 2020-05-19 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390020012897/0001213900-20-012897-index.htm |
| 2020-05-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020013443/0001213900-20-013443-index.htm |
| 2020-06-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020013937/0001213900-20-013937-index.htm |
| 2020-06-05 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1506251/000121390020014231/0001213900-20-014231-index.htm |
| 2020-06-11 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1506251/000121390020014691/0001213900-20-014691-index.htm |
| 2020-06-12 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1506251/000121390020014875/0001213900-20-014875-index.htm |
| 2020-06-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020015902/0001213900-20-015902-index.htm |
| 2020-07-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390020017075/0001213900-20-017075-index.htm |
| 2020-07-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390020017080/0001213900-20-017080-index.htm |
| 2020-07-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390020017083/0001213900-20-017083-index.htm |
| 2020-07-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390020017086/0001213900-20-017086-index.htm |
| 2020-07-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390020017089/0001213900-20-017089-index.htm |
| 2020-07-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020017179/0001213900-20-017179-index.htm |
| 2020-07-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020017402/0001213900-20-017402-index.htm |
| 2020-07-15 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390020017556/0001213900-20-017556-index.htm |
| 2020-07-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390020017558/0001213900-20-017558-index.htm |
| 2020-08-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020020036/0001213900-20-020036-index.htm |
| 2020-08-05 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1506251/000121390020020405/0001213900-20-020405-index.htm |
| 2020-08-05 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1506251/000121390020020409/0001213900-20-020409-index.htm |
| 2020-08-06 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1506251/000121390020020467/0001213900-20-020467-index.htm |
| 2020-08-07 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1506251/000121390020020900/0001213900-20-020900-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020021164/0001213900-20-021164-index.htm |
| 2020-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1506251/000121390020022331/0001213900-20-022331-index.htm |
| 2020-08-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020023749/0001213900-20-023749-index.htm |
| 2020-08-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020023818/0001213900-20-023818-index.htm |
| 2020-09-11 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1506251/000121390020026248/0001213900-20-026248-index.htm |
| 2020-09-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020026724/0001213900-20-026724-index.htm |
| 2020-09-18 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1506251/000121390020027371/0001213900-20-027371-index.htm |
| 2020-09-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020027841/0001213900-20-027841-index.htm |
| 2020-09-25 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1506251/000121390020028490/0001213900-20-028490-index.htm |
| 2020-09-25 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1506251/000121390020028494/0001213900-20-028494-index.htm |
| 2020-09-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020028857/0001213900-20-028857-index.htm |
| 2020-10-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390020030788/0001213900-20-030788-index.htm |
| 2020-10-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390020030790/0001213900-20-030790-index.htm |
| 2020-10-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390020030791/0001213900-20-030791-index.htm |
| 2020-10-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390020030792/0001213900-20-030792-index.htm |
| 2020-10-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390020030793/0001213900-20-030793-index.htm |
| 2020-10-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390020030794/0001213900-20-030794-index.htm |
| 2020-10-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390020030795/0001213900-20-030795-index.htm |
| 2020-10-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1506251/000121390020030797/0001213900-20-030797-index.htm |
| 2020-10-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020030802/0001213900-20-030802-index.htm |
| 2020-10-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1506251/000121390020033152/0001213900-20-033152-index.htm |
| 2020-04-24 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1506251/999999999520000856/9999999995-20-000856-index.htm |
| 2020-06-12 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1506251/999999999520001419/9999999995-20-001419-index.htm |
| 2020-09-25 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1506251/999999999520002581/9999999995-20-002581-index.htm |
| 2020-09-30 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1506251/999999999520002620/9999999995-20-002620-index.htm |